SEO URLwww.firestrike.ai/deals/corstasis-therapeutics-esperion-acquisition-2026-2

acquisitionAnnounced · Mar 3, 2026cardiovascularSource · CredibleArticle · Factual

Corstasis Therapeutics · Esperion

Esperion acquires Corstasis Therapeutics

David Najork · Founding Software Engineer

Published Apr 29, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

—

Target

Corstasis Therapeutics

Henderson, Nevada

Acquirer

Esperion

Full Acquisition

Status

Announced

Esperion agreed to acquire Corstasis Therapeutics. Reported deal value: Undisclosed. Status: Announced. Sector: cardiovascular. Target headquarters context: Henderson, Nevada, United States.

This page summarizes publicly available information about the transaction as of 2026-03-03. Figures and status may change as filings and press coverage update.

Esperion and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular , and hepatic and renal disease, today announced they have entered into a definitive agreement for Esperion to acquire Corstasis

Deal timeline

Announced

Mar 3, 2026 · biospace.com

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in cardiovascular. Figures and status may change as sources update.

Sources: biospace.com · Primary article · FireStrike proprietary index